A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy.
MET
aktiv
2
Georgstraße 12
26121 Oldenburg
Tel: 0441 / 229 0
Fax: 0441 / 229 1607
Frank.Griesinger@Pius-Hospital.de
www.pius-hospital.de/kontakt
Professor Dr. med. Frank Griesinger
Pius-Hospital Oldenburg
Klinik für Hämatologie und Onkologie
Universitätsklinik Innere Medizin-Onkologie
Medizinischer Campus Universität Oldenburg
+49 (0) 800 / 0005605 
info@nowel.org